1. Home
  2. VOC vs NXTC Comparison

VOC vs NXTC Comparison

Compare VOC & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

VOC

VOC Energy Trust Units of Beneficial Interest

HOLD

Current Price

$2.91

Market Cap

48.8M

Sector

Energy

ML Signal

HOLD

Logo NextCure Inc.

NXTC

NextCure Inc.

HOLD

Current Price

$2.07

Market Cap

39.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VOC
NXTC
Founded
2010
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
48.8M
39.1M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
VOC
NXTC
Price
$2.91
$2.07
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$23.00
AVG Volume (30 Days)
55.1K
125.1K
Earning Date
01-01-0001
05-04-2026
Dividend Yield
12.46%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$22,378,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$6.00
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.60
$1.55
52 Week High
$3.84
$15.74

Technical Indicators

Market Signals
Indicator
VOC
NXTC
Relative Strength Index (RSI) 51.56 32.62
Support Level $2.81 $1.55
Resistance Level $3.11 $10.81
Average True Range (ATR) 0.08 0.33
MACD 0.03 0.29
Stochastic Oscillator 89.16 64.81

Price Performance

Historical Comparison
VOC
NXTC

About VOC VOC Energy Trust Units of Beneficial Interest

VOC Energy Trust is a statutory trust. It is created to acquire and hold a term net profits interest for the benefit of the Trust unitholders. The underlying properties include VOC Brazos' net interests which are located in the states of Kansas and Texas. The trust is entitled to receive the net proceeds from the sale of production of oil and natural gas attributable to the underlying properties. The business and affairs of the Trust are managed by the Trustee, and neither VOC Brazos nor any of its affiliates has the ability to manage or influence the operations of the Trust. It operates in a single operating and reportable segment.

About NXTC NextCure Inc.

NextCure Inc is a clinical-stage biopharmaceutical company that is focused on advancing inventive medicines that treat cancer patients that do not respond to, or that have disease progression on, current therapies, through the use of targeted therapies including antibody-drug conjugates. The company's product candidates include NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.

Share on Social Networks: